Abbott Surges 1.09% on $1.57B Trade Volume Leap to 132th as Strategic Partnership Boosts Investor Confidence in Home Health Monitoring Expansion

. 19, , . The move followed a regulatory filing disclosing plans to expand its diagnostic testing portfolio through a partnership with a European biotech firm, a strategic shift highlighted in internal communications reviewed by Bloomberg.

Analysts noted the volume surge reflects heightened investor confidence in the company’s long-term positioning amid rising demand for at-home health monitoring solutions. The partnership, , was cited as a key driver for near-term optimism, though no immediate earnings impacts were quantified in the announcement.

To run this back-test accurately, I need to clarify a few implementation details: 1. Market universe — Do you want all U.S. listed equities (NYSE + Nasdaq + Amex), or a different market/universe? 2. Weighting and execution price — Should the 500 selected stocks be held in equal-weight, using next-day open prices to enter and the following day’s open (or close) to exit? 3. Transaction costs / slippage — Would you like to impose commission or slippage assumptions? If so, what values? 4. Benchmark (optional) — Should I compare the strategy against any benchmark index? Let me know, and I’ll set the back-test up for you.